多替阿巴拉米片去哪里可以买到？

GlaxoSmithKline (GSK) announced in 2017 that its joint venture, ViiV Healthcare1, a new compound preparation for AIDS treatment Suimeikai (chemical name:), has received marketing approval from the China Food and Drug Administration (CFDA). As an innovative single-pill compound preparation with obvious clinical therapeutic advantages, Suimeikai can provide great convenience for the treatment of AIDS patients. As a new AIDS treatment drug, Suimeikai has received priority review and approval from the CFDA.

Suimeike is the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. It can be taken once a day, one tablet each time, which can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

According to Medical Companion Travel, the price of Suimeikan (Abalamid Tablets, Inbec) available in China is relatively expensive, and most patients cannot afford it. The domestic price of Suimeike (Abalamid Tablets, Inbec) in China is 2,880$/month. Patients who cannot afford domestic Suimeike (Dolutea, Inbec) can choose to buy Suimeike (Dolutea, Inbec) which is available in India, and the price is relatively cheap. Suimeike (Abalamid Tablets, Inbec) produced by the Indian company Emcure, comes in a box of 30 tablets, priced at approximately RMB 1,000.

Currently, patients who want to buy it can buy it domestically, but domestic drugs are relatively expensive. Patients can also choose to go abroad to buy the Indian version of Dolutegra Abalamid tablets, which are more affordable. Some patients who are unable to go abroad can find a professional overseas medical service agency (such as Medical Companion Travel) in China. For details, consult the Medical Companion Travel Service.